Lates News

According to Every Jing AI flash news, Donghai Securities issued a research report on April 20th, giving a "buy" rating to Di Zhe Pharmaceutical (688192.SH). The main reasons for the rating include: 1) rapid commercialization of products; 2) successful international Phase III clinical trial of Shuwotini as a first-line treatment for EGFR exon20ins NSCLC; 3) extensive layout of blood cancer pipeline. (Daily Economic News)